Analystreport

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.

Intra-Cellular Therapies Inc.  (ITCI) 
Last intra-cellular therapies inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intracellulartherapies.com/investor-relations